Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Ongoing Initiated Apr 21, 2022 (4 years ago)

Halobetasol Propionate Ointment 0.05% Net Wt.

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

CGMP Deviations: all products within expiry are being recalled because the manufacturing firm, Teligent Pharma, Inc.is discontinuing its stability study program.

Cause type: Stability / shelf life

The product degraded or failed stability testing before its labeled expiry. Heat, moisture or time can break the drug down into degradants or reduce potency. All stability / shelf life recalls.

What was recalled

Halobetasol Propionate Ointment 0.05% Net Wt., 50 gram tube, Rx Only, Manufactured by: Teligent Pharma, Inc. Buena, NJ 08310, Distributed by: McKesson Corporation dba Sky Packaging 4071 Southridge Blvd., Suite 101 Memphis, TN 38141, NDC 63739-998-67

Affected NDC 63739-0998-67

Compare with the code on your package — it is the most precise check available.

Drug: Halobetasol

Recalling firm
McKesson Corporation dba McKesson Drug Company
NDC code
63739-998-67
Origin
TN, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0847-2022 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall.

Other Halobetasol recalls

See all
Class II · Moderate risk

Halobetasol Propionate Ointment

cGMP deviations: all products within expiry are being recalled because the firm is discontinuing its stability study program.

Terminated Stability / shelf life Teligent Pharma, Inc. NDC 63739-998-67 D-0691-2022
Class II · Moderate risk

Halobetasol Propionate Ointment

cGMP deviations: all products within expiry are being recalled because the firm is discontinuing its stability study program.

Terminated Stability / shelf life Teligent Pharma, Inc. NDC 52565-073-15 D-0689-2022
Class II · Moderate risk

Halobetasol Propionate Ointment

cGMP deviations: all products within expiry are being recalled because the firm is discontinuing its stability study program.

Terminated Stability / shelf life Teligent Pharma, Inc. NDC 70512-033-50 D-0688-2022
Class II · Moderate risk

Lexette (halobetasol propionate)

CGMP Deviation: Difficulty dispensing/does not dispense or dispensing liquid instead of foam.

Ongoing cGMP deviation Mayne Pharma Inc NDC 51862-604-50 D-0387-2022
Class II · Moderate risk

Halobetasol Propionate active pharmaceutical ingredient packaged…

Penicillin Cross Contamination: All lots of all products repackaged and distributed between 01/05/12 and 02/12/15 are being recalled because they were repackaged in a facility with penicillin products without adequate separation which could introduce the potential for cross contamination with penicillin.

Terminated Cross-contamination Attix Pharmaceuticals D-702-2015

Other recalls by McKesson Corporation dba McKesson Drug Company

All 2022 recalls
Class II · Moderate risk

Gemcitabine Injection

Temperature Abuse: Product was stored incorrectly in a controlled room temperature environment instead of a refrigerated environment.

Ongoing Temperature excursion McKesson D-0714-2026
Class I · High risk

Udenyca

Temperature Abuse. 116 cartons with specific serial numbers of Lot 2199821, were stored incorrectly in a controlled room temperature environment instead of the required refrigerated environment.

Ongoing Temperature excursion McKesson NDC 69448-025-63 D-0353-2026
Class II · Moderate risk

Inflectra (infliximab-dyyb)

cGMP Deviations: Product intended for quarantine was inadvertently distributed.

Ongoing cGMP deviation McKesson NDC 0069-0809-01 D-0213-2025